Loading…
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: TRAVERE THERAPEUTICS · Firm: TRAVERE THERAPEUTICS
Regulations regarding transparency, reimbursement and care, particularly regarding rare disease. Medicare and Medicaid related provisions in H.R.1, One Big Beautiful Bill Act.
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: TRAVERE THERAPEUTICS · Firm: TRAVERE THERAPEUTICS
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
TRAVERE THERAPEUTICS via TRAVERE THERAPEUTICS
2026 · third_quarter · Q3
Legislation regarding the Orphan Drug Act and rare disease diagnosis, treatment, and care. Legislation regarding kidney disease and in particular rare kidney disease. HR 1518, the New Era of Preventing End-Stage Kidney Disease Act; end-stage renal disease policy and rare kidney disease; HR 10571, the Surge to Save Newborns Act
S.1040, to prohibit product hopping and for other purposes; proposals regarding patent thickets. S. 2658, Medication Affordability and Patent Integrity Act
Source: Senate LDA
Regulations regarding transparency, reimbursement and care, particularly regarding rare disease. Medicare and Medicaid related provisions in H.R.1, One Big Beautiful Bill Act.H.R. 9509, the Kidney Disease Education Expansion Act
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: TRAVERE THERAPEUTICS · Firm: TRAVERE THERAPEUTICS
H.R. 1414, Cameron's Law to increase Orphan Drug Tax Credit to 50%; R&D tax credit; related implementation provisions in H.R.1, One Big Beautiful Bill Act; pharmaceutical tariffs, specifically related to orphan drugs
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: TRAVERE THERAPEUTICS · Firm: TRAVERE THERAPEUTICS
HR 946 and S. 1862, Optimizing Research Progress Hope and New Cures (ORPHAN Cures Act); related provisions in H.R.1, One Big Beautiful Bill Act; Most Favored Nation and international reference pricing proposals
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: TRAVERE THERAPEUTICS · Firm: TRAVERE THERAPEUTICS
Regulations regarding transparency, reimbursement and care, particularly regarding rare disease. Medicare and Medicaid related provisions in H.R.1, One Big Beautiful Bill Act.H.R. 9509, the Kidney Disease Education Expansion Act
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: TRAVERE THERAPEUTICS · Firm: TRAVERE THERAPEUTICS
H.R. 1414, Cameron's Law to increase Orphan Drug Tax Credit to 50%; R&D tax credit; related implementation provisions in H.R.1, One Big Beautiful Bill Act; pharmaceutical tariffs, specifically related to orphan drugs
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: TRAVERE THERAPEUTICS · Firm: TRAVERE THERAPEUTICS
HR 1262, S 932 Give Kids a Chance Act to renew PRV program; related provisions in H.R.1, One Big Beautiful Bill Act; HR 4709, the Newborn Screening Saves Lives Reauthorization Act; PDUFA/regulatory review process; H.R. 9102, Biotech Investment National Security Act (BINSA); H.R. 10359, Priority for Pediatric Cures Act to make PRV permanent
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: TRAVERE THERAPEUTICS · Firm: TRAVERE THERAPEUTICS
HR 946 and S. 1862, Optimizing Research Progress Hope and New Cures (ORPHAN Cures Act); related provisions in H.R.1, One Big Beautiful Bill Act; Most Favored Nation and international reference pricing proposals
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: TRAVERE THERAPEUTICS · Firm: TRAVERE THERAPEUTICS
HR 946 and S. 1862, Optimizing Research Progress Hope and New Cures (ORPHAN Cures Act); related provisions in H.R.1, One Big Beautiful Bill Act; Most Favored Nation and international reference pricing proposals
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: TRAVERE THERAPEUTICS · Firm: TRAVERE THERAPEUTICS
HR 1262, S 932 Give Kids a Chance Act to renew PRV program; related provisions in H.R.1, One Big Beautiful Bill Act; HR 4709, the Newborn Screening Reauthorization Act; PDUFA/regulatory review process
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: TRAVERE THERAPEUTICS · Firm: TRAVERE THERAPEUTICS
H.R. 1414, Cameron's Law to increase Orphan Drug Tax Credit to 50%; R&D tax credit; related implementation provisions in H.R.1, One Big Beautiful Bill Act; tariffs
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: TRAVERE THERAPEUTICS · Firm: TRAVERE THERAPEUTICS
HR 1262, S 932 Give Kids a Chance Act to renew PRV program; related provisions in H.R.1, One Big Beautiful Bill Act; HR 4709, the Newborn Screening Saves Lives Reauthorization Act; PDUFA/regulatory review process; H.R. 9102, Biotech Investment National Security Act (BINSA)
HR 1262, S 932 Give Kids a Chance Act to renew PRV program; related provisions in H.R.1, One Big Beautiful Bill Act; HR 4709, the Newborn Screening Saves Lives Reauthorization Act; PDUFA/regulatory review process; H.R. 9102, Biotech Investment National Security Act (BINSA); H.R. 10359, Priority for Pediatric Cures Act to make PRV permanent
Legislation regarding the Orphan Drug Act and rare disease diagnosis, treatment, and care. Legislation regarding kidney disease and in particular rare kidney disease. HR 1518, the New Era of Preventing End-Stage Kidney Disease Act; end-stage renal disease policy and rare kidney disease; HR 10571, the Surge to Save Newborns Act
Mikaela Naylon Give Kids a Chance Act
Client: TRAVERE THERAPEUTICS · Firm: TRAVERE THERAPEUTICS
HR 1262, S 932 Give Kids a Chance Act to renew PRV program; related provisions in H.R.1, One Big Beautiful Bill Act; HR 4709, the Newborn Screening Saves Lives Reauthorization Act; PDUFA/regulatory review process; H.R. 9102, Biotech Investment National Security Act (BINSA)
Mikaela Naylon Give Kids a Chance Act
Client: TRAVERE THERAPEUTICS · Firm: TRAVERE THERAPEUTICS
HR 1262, S 932 Give Kids a Chance Act to renew PRV program; related provisions in H.R.1, One Big Beautiful Bill Act; HR 4709, the Newborn Screening Saves Lives Reauthorization Act; PDUFA/regulatory review process; H.R. 9102, Biotech Investment National Security Act (BINSA); H.R. 10359, Priority for Pediatric Cures Act to make PRV permanent
Mikaela Naylon Give Kids a Chance Act
Client: TRAVERE THERAPEUTICS · Firm: TRAVERE THERAPEUTICS
HR 1262, S 932 Give Kids a Chance Act to renew PRV program; related provisions in H.R.1, One Big Beautiful Bill Act; HR 4709, the Newborn Screening Reauthorization Act; PDUFA/regulatory review process
H.R. 1414, Cameron's Law to increase Orphan Drug Tax Credit to 50%; R&D tax credit; related implementation provisions in H.R.1, One Big Beautiful Bill Act; tariffs
H.R. 1414, Cameron's Law to increase Orphan Drug Tax Credit to 50%; R&D tax credit; related implementation provisions in H.R.1, One Big Beautiful Bill Act; pharmaceutical tariffs, specifically related to orphan drugs
H.R. 1414, Cameron's Law to increase Orphan Drug Tax Credit to 50%; R&D tax credit; related implementation provisions in H.R.1, One Big Beautiful Bill Act; pharmaceutical tariffs, specifically related to orphan drugs
New Era of Preventing End-Stage Kidney Disease Act
Client: TRAVERE THERAPEUTICS · Firm: TRAVERE THERAPEUTICS
Legislation regarding the Orphan Drug Act and rare disease diagnosis, treatment, and care. Legislation regarding kidney disease and in particular rare kidney disease. HR 1518, the New Era of Preventing End-Stage Kidney Disease Act; end-stage renal disease policy and rare kidney disease; HR 10571, the Surge to Save Newborns Act
New Era of Preventing End-Stage Kidney Disease Act
Client: TRAVERE THERAPEUTICS · Firm: TRAVERE THERAPEUTICS
Legislation regarding the Orphan Drug Act and rare disease diagnosis, treatment, and care. Legislation regarding kidney disease and in particular rare kidney disease. HR 1518, the New Era of Preventing End-Stage Kidney Disease Act; end-stage renal disease policy and rare kidney disease
New Era of Preventing End-Stage Kidney Disease Act
Client: TRAVERE THERAPEUTICS · Firm: TRAVERE THERAPEUTICS
Legislation regarding the Orphan Drug Act and rare disease diagnosis, treatment, and care. Legislation regarding kidney disease and in particular rare kidney disease. HR 1518, the New Era of Preventing End-Stage Kidney Disease Act; end-stage renal disease policy and rare kidney disease
Newborn Screening Saves Lives Reauthorization Act of 2025
Client: TRAVERE THERAPEUTICS · Firm: TRAVERE THERAPEUTICS
HR 1262, S 932 Give Kids a Chance Act to renew PRV program; related provisions in H.R.1, One Big Beautiful Bill Act; HR 4709, the Newborn Screening Saves Lives Reauthorization Act; PDUFA/regulatory review process; H.R. 9102, Biotech Investment National Security Act (BINSA); H.R. 10359, Priority for Pediatric Cures Act to make PRV permanent
Newborn Screening Saves Lives Reauthorization Act of 2025
Client: TRAVERE THERAPEUTICS · Firm: TRAVERE THERAPEUTICS
HR 1262, S 932 Give Kids a Chance Act to renew PRV program; related provisions in H.R.1, One Big Beautiful Bill Act; HR 4709, the Newborn Screening Saves Lives Reauthorization Act; PDUFA/regulatory review process; H.R. 9102, Biotech Investment National Security Act (BINSA)
Newborn Screening Saves Lives Reauthorization Act of 2025
Client: TRAVERE THERAPEUTICS · Firm: TRAVERE THERAPEUTICS
HR 1262, S 932 Give Kids a Chance Act to renew PRV program; related provisions in H.R.1, One Big Beautiful Bill Act; HR 4709, the Newborn Screening Reauthorization Act; PDUFA/regulatory review process
HR 1262, S 932 Give Kids a Chance Act to renew PRV program; related provisions in H.R.1, One Big Beautiful Bill Act; HR 4709, the Newborn Screening Saves Lives Reauthorization Act; PDUFA/regulatory review process; H.R. 9102, Biotech Investment National Security Act (BINSA); H.R. 10359, Priority for Pediatric Cures Act to make PRV permanent
HR 1262, S 932 Give Kids a Chance Act to renew PRV program; related provisions in H.R.1, One Big Beautiful Bill Act; HR 4709, the Newborn Screening Saves Lives Reauthorization Act; PDUFA/regulatory review process; H.R. 9102, Biotech Investment National Security Act (BINSA)
HR 946 and S. 1862, Optimizing Research Progress Hope and New Cures (ORPHAN Cures Act); related provisions in H.R.1, One Big Beautiful Bill Act; Most Favored Nation and international reference pricing proposals
HR 946 and S. 1862, Optimizing Research Progress Hope and New Cures (ORPHAN Cures Act); related provisions in H.R.1, One Big Beautiful Bill Act; Most Favored Nation and international reference pricing proposals
HR 946 and S. 1862, Optimizing Research Progress Hope and New Cures (ORPHAN Cures Act); related provisions in H.R.1, One Big Beautiful Bill Act; Most Favored Nation and international reference pricing proposals
Kidney Disease Education Access Expansion Act of 2026
Client: TRAVERE THERAPEUTICS · Firm: TRAVERE THERAPEUTICS
Regulations regarding transparency, reimbursement and care, particularly regarding rare disease. Medicare and Medicaid related provisions in H.R.1, One Big Beautiful Bill Act.H.R. 9509, the Kidney Disease Education Expansion Act
Kidney Disease Education Access Expansion Act of 2026
Client: TRAVERE THERAPEUTICS · Firm: TRAVERE THERAPEUTICS
Regulations regarding transparency, reimbursement and care, particularly regarding rare disease. Medicare and Medicaid related provisions in H.R.1, One Big Beautiful Bill Act.H.R. 9509, the Kidney Disease Education Expansion Act
S.1040, to prohibit product hopping and for other purposes; proposals regarding patent thickets
S.1040, to prohibit product hopping and for other purposes; proposals regarding patent thickets. S. 2658, Medication Affordability and Patent Integrity Act
S.1040, to prohibit product hopping and for other purposes; proposals regarding patent thickets. S. 2658, Medication Affordability and Patent Integrity Act
HR 946 and S. 1862, Optimizing Research Progress Hope and New Cures (ORPHAN Cures Act); related provisions in H.R.1, One Big Beautiful Bill Act; Most Favored Nation and international reference pricing proposals
HR 946 and S. 1862, Optimizing Research Progress Hope and New Cures (ORPHAN Cures Act); related provisions in H.R.1, One Big Beautiful Bill Act; Most Favored Nation and international reference pricing proposals
HR 946 and S. 1862, Optimizing Research Progress Hope and New Cures (ORPHAN Cures Act); related provisions in H.R.1, One Big Beautiful Bill Act; Most Favored Nation and international reference pricing proposals
Medication Affordability and Patent Integrity Act
Client: TRAVERE THERAPEUTICS · Firm: TRAVERE THERAPEUTICS
S.1040, to prohibit product hopping and for other purposes; proposals regarding patent thickets. S. 2658, Medication Affordability and Patent Integrity Act
Medication Affordability and Patent Integrity Act
Client: TRAVERE THERAPEUTICS · Firm: TRAVERE THERAPEUTICS
S.1040, to prohibit product hopping and for other purposes; proposals regarding patent thickets. S. 2658, Medication Affordability and Patent Integrity Act
HR 1262, S 932 Give Kids a Chance Act to renew PRV program; related provisions in H.R.1, One Big Beautiful Bill Act; HR 4709, the Newborn Screening Saves Lives Reauthorization Act; PDUFA/regulatory review process; H.R. 9102, Biotech Investment National Security Act (BINSA)
HR 1262, S 932 Give Kids a Chance Act to renew PRV program; related provisions in H.R.1, One Big Beautiful Bill Act; HR 4709, the Newborn Screening Reauthorization Act; PDUFA/regulatory review process
HR 1262, S 932 Give Kids a Chance Act to renew PRV program; related provisions in H.R.1, One Big Beautiful Bill Act; HR 4709, the Newborn Screening Saves Lives Reauthorization Act; PDUFA/regulatory review process; H.R. 9102, Biotech Investment National Security Act (BINSA); H.R. 10359, Priority for Pediatric Cures Act to make PRV permanent
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: TRAVERE THERAPEUTICS · Firm: TRAVERE THERAPEUTICS
HR 946 and S. 1862, Optimizing Research Progress Hope and New Cures (ORPHAN Cures Act); related provisions in H.R.1, One Big Beautiful Bill Act; Most Favored Nation and international reference pricing proposals
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: TRAVERE THERAPEUTICS · Firm: TRAVERE THERAPEUTICS
HR 946 and S. 1862, Optimizing Research Progress Hope and New Cures (ORPHAN Cures Act); related provisions in H.R.1, One Big Beautiful Bill Act; Most Favored Nation and international reference pricing proposals
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: TRAVERE THERAPEUTICS · Firm: TRAVERE THERAPEUTICS
HR 1262, S 932 Give Kids a Chance Act to renew PRV program; related provisions in H.R.1, One Big Beautiful Bill Act; HR 4709, the Newborn Screening Reauthorization Act
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: TRAVERE THERAPEUTICS · Firm: TRAVERE THERAPEUTICS
H.R. 1414, Cameron's Law to increase Orphan Drug Tax Credit to 50%; R&D tax credit; related provisions in H.R.1, One Big Beautiful Bill Act; tariffs
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: TRAVERE THERAPEUTICS · Firm: TRAVERE THERAPEUTICS
Regulations regarding transparency, reimbursement and care, particularly regarding rare disease. Medicare and Medicaid related provisions in H.R.1, One Big Beautiful Bill Act.
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: TRAVERE THERAPEUTICS · Firm: TRAVERE THERAPEUTICS
HR 1262, S 932 Give Kids a Chance Act to renew PRV program; related provisions in H.R.1, One Big Beautiful Bill Act
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: TRAVERE THERAPEUTICS · Firm: TRAVERE THERAPEUTICS
H.R. 1414, Cameron's Law to increase Orphan Drug Tax Credit to 50%; R&D tax credit; related provisions in H.R.1, One Big Beautiful Bill Act; tariffs
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: TRAVERE THERAPEUTICS · Firm: TRAVERE THERAPEUTICS
HR 946 and S. 1862, Optimizing Research Progress Hope and New Cures (ORPHAN Cures Act); related provisions in H.R.1, One Big Beautiful Bill Act; Most Favored Nation and international reference pricing proposals
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: TRAVERE THERAPEUTICS · Firm: TRAVERE THERAPEUTICS
H.R. 1414, Cameron's Law to increase Orphan Drug Tax Credit to 50%; R&D tax credit; related provisions in H.R.1, One Big Beautiful Bill Act; tariffs
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: TRAVERE THERAPEUTICS · Firm: TRAVERE THERAPEUTICS
HR 1262, S 932 Give Kids a Chance Act to renew PRV program; related provisions in H.R.1, One Big Beautiful Bill Act; HR 4709, the Newborn Screening Reauthorization Act
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: TRAVERE THERAPEUTICS · Firm: TRAVERE THERAPEUTICS
Regulations regarding transparency, reimbursement and care, particularly regarding rare disease. Medicare and Medicaid related provisions in H.R.1, One Big Beautiful Bill Act.
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: TRAVERE THERAPEUTICS · Firm: TRAVERE THERAPEUTICS
Regulations regarding transparency, reimbursement and care, particularly regarding rare disease. Medicare and Medicaid related provisions in H.R.1, One Big Beautiful Bill Act.
Mikaela Naylon Give Kids a Chance Act
Client: TRAVERE THERAPEUTICS · Firm: TRAVERE THERAPEUTICS
HR 1262, S 932 Give Kids a Chance Act to renew PRV program; related provisions in H.R.1, One Big Beautiful Bill Act
Mikaela Naylon Give Kids a Chance Act
Client: TRAVERE THERAPEUTICS · Firm: TRAVERE THERAPEUTICS
HR 1262, S 932 Give Kids a Chance Act to renew PRV program
Mikaela Naylon Give Kids a Chance Act
Client: TRAVERE THERAPEUTICS · Firm: TRAVERE THERAPEUTICS
HR 1262, S 932 Give Kids a Chance Act to renew PRV program; related provisions in H.R.1, One Big Beautiful Bill Act; HR 4709, the Newborn Screening Reauthorization Act
Mikaela Naylon Give Kids a Chance Act
Client: TRAVERE THERAPEUTICS · Firm: TRAVERE THERAPEUTICS
HR 1262, S 932 Give Kids a Chance Act to renew PRV program; related provisions in H.R.1, One Big Beautiful Bill Act; HR 4709, the Newborn Screening Reauthorization Act
H.R. 1414, Cameron's Law to increase Orphan Drug Tax Credit to 50%; R&D tax credit; related provisions in H.R.1, One Big Beautiful Bill Act; tariffs
H.R. 1414, Cameron's Law to increase Orphan Drug Tax Credit to 50%
H.R. 1414, Cameron's Law to increase Orphan Drug Tax Credit to 50%; R&D tax credit; related provisions in H.R.1, One Big Beautiful Bill Act; tariffs
H.R. 1414, Cameron's Law to increase Orphan Drug Tax Credit to 50%; R&D tax credit; related provisions in H.R.1, One Big Beautiful Bill Act; tariffs
New Era of Preventing End-Stage Kidney Disease Act
Client: TRAVERE THERAPEUTICS · Firm: TRAVERE THERAPEUTICS
Legislation regarding the Orphan Drug Act and rare disease diagnosis, treatment, and care. Legislation regarding kidney disease and in particular rare kidney disease. HR 1518, the New Era of Preventing End-Stage Kidney Disease Act
New Era of Preventing End-Stage Kidney Disease Act
Client: TRAVERE THERAPEUTICS · Firm: TRAVERE THERAPEUTICS
Legislation regarding the Orphan Drug Act and rare disease diagnosis, treatment, and care. Legislation regarding kidney disease and in particular rare kidney disease. HR 1518, the New Era of Preventing End-Stage Kidney Disease Act
New Era of Preventing End-Stage Kidney Disease Act
Client: TRAVERE THERAPEUTICS · Firm: TRAVERE THERAPEUTICS
Legislation regarding the Orphan Drug Act and rare disease diagnosis, treatment, and care. Legislation regarding kidney disease and in particular rare kidney disease. HR 1518, the New Era of Preventing End-Stage Kidney Disease Act
New Era of Preventing End-Stage Kidney Disease Act
Client: TRAVERE THERAPEUTICS · Firm: TRAVERE THERAPEUTICS
Legislation regarding the Orphan Drug Act and rare disease diagnosis, treatment, and care. Legislation regarding kidney disease and in particular rare kidney disease. HR 1518, the New Era of Preventing End-Stage Kidney Disease Act
Newborn Screening Saves Lives Reauthorization Act of 2025
Client: TRAVERE THERAPEUTICS · Firm: TRAVERE THERAPEUTICS
HR 1262, S 932 Give Kids a Chance Act to renew PRV program; related provisions in H.R.1, One Big Beautiful Bill Act; HR 4709, the Newborn Screening Reauthorization Act
Newborn Screening Saves Lives Reauthorization Act of 2025
Client: TRAVERE THERAPEUTICS · Firm: TRAVERE THERAPEUTICS
HR 1262, S 932 Give Kids a Chance Act to renew PRV program; related provisions in H.R.1, One Big Beautiful Bill Act; HR 4709, the Newborn Screening Reauthorization Act
HR 946, Optimizing Research Progress Hope and New Cures (ORPHAN Cures Act)
HR 946 and S. 1862, Optimizing Research Progress Hope and New Cures (ORPHAN Cures Act); related provisions in H.R.1, One Big Beautiful Bill Act; Most Favored Nation and international reference pricing proposals
HR 946 and S. 1862, Optimizing Research Progress Hope and New Cures (ORPHAN Cures Act); related provisions in H.R.1, One Big Beautiful Bill Act; Most Favored Nation and international reference pricing proposals
HR 946 and S. 1862, Optimizing Research Progress Hope and New Cures (ORPHAN Cures Act); related provisions in H.R.1, One Big Beautiful Bill Act; Most Favored Nation and international reference pricing proposals
S.1040, to prohibit product hopping and for other purposes; proposals regarding patent thickets
S.1040, to prohibit product hopping and for other purposes
S.1040, to prohibit product hopping and for other purposes
S.1040, to prohibit product hopping and for other purposes
HR 946 and S. 1862, Optimizing Research Progress Hope and New Cures (ORPHAN Cures Act); related provisions in H.R.1, One Big Beautiful Bill Act; Most Favored Nation and international reference pricing proposals
HR 946 and S. 1862, Optimizing Research Progress Hope and New Cures (ORPHAN Cures Act); related provisions in H.R.1, One Big Beautiful Bill Act; Most Favored Nation and international reference pricing proposals
HR 946 and S. 1862, Optimizing Research Progress Hope and New Cures (ORPHAN Cures Act); related provisions in H.R.1, One Big Beautiful Bill Act; Most Favored Nation and international reference pricing proposals
HR 1262, S 932 Give Kids a Chance Act to renew PRV program; related provisions in H.R.1, One Big Beautiful Bill Act; HR 4709, the Newborn Screening Reauthorization Act
HR 1262, S 932 Give Kids a Chance Act to renew PRV program
HR 1262, S 932 Give Kids a Chance Act to renew PRV program; related provisions in H.R.1, One Big Beautiful Bill Act; HR 4709, the Newborn Screening Reauthorization Act
HR 1262, S 932 Give Kids a Chance Act to renew PRV program; related provisions in H.R.1, One Big Beautiful Bill Act
Further Continuing Appropriations and Disaster Relief Supplemental Appropriations Act, 2025
Client: TRAVERE THERAPEUTICS · Firm: TRAVERE THERAPEUTICS
Legislation regarding FDA and clinical research, particularly with respect to rare disease and orphan drug development and the accelerated approval pathway, and related legislation regarding FY 2024 Appropriations. FY 2025 appropriations for CDC newborn screening programs. HR 7384/S. 4583, Creating Hope Reauthorization Act to renew PRV program. HR 10445, the Continuing Resolution and provisions related to the PRV program.
Legislation regarding the Orphan Drug Tax Credit. H.R. 1350, Cameron's Law. H.R. 1805, Leo's Law.
Legislation regarding the Orphan Drug Tax Credit. H.R. 1350, Cameron's Law. H.R. 1805, Leo's Law.
Legislation regarding the Orphan Drug Tax Credit. H.R. 1350, Cameron's Law. H.R. 1805, Leo's Law.
Legislation regarding the Orphan Drug Tax Credit. H.R. 1350, Cameron's Law. H.R. 1805, Leo's Law.
Legislation regarding the Orphan Drug Tax Credit. H.R. 1350, Cameron's Law. H.R. 1805, Leo's Law.
Legislation regarding the Orphan Drug Tax Credit. H.R. 1350, Cameron's Law. H.R. 1805, Leo's Law.
Legislation regarding the Orphan Drug Tax Credit. H.R. 1350, Cameron's Law. H.R. 1805, Leo's Law.
Legislation regarding the Orphan Drug Tax Credit. H.R. 1350, Cameron's Law. H.R. 1805, Leo's Law.
New Era of Preventing End-Stage Kidney Disease Act
Client: TRAVERE THERAPEUTICS · Firm: TRAVERE THERAPEUTICS
Legislation regarding the Orphan Drug Act and rare disease diagnosis, treatment, and care. Legislation regarding kidney disease and in particular rare kidney disease. HR 6790, the New Era of Preventing End-Stage Kidney Disease Act
New Era of Preventing End-Stage Kidney Disease Act
Client: TRAVERE THERAPEUTICS · Firm: TRAVERE THERAPEUTICS
Legislation regarding the Orphan Drug Act and rare disease diagnosis, treatment, and care. Legislation regarding kidney disease and in particular rare kidney disease. HR 6790, the New Era of Preventing End-Stage Kidney Disease Act
New Era of Preventing End-Stage Kidney Disease Act
Client: TRAVERE THERAPEUTICS · Firm: TRAVERE THERAPEUTICS
Legislation regarding the Orphan Drug Act and rare disease diagnosis, treatment, and care. Legislation regarding kidney disease and in particular rare kidney disease. HR 6790, the New Era of Preventing End-Stage Kidney Disease Act
New Era of Preventing End-Stage Kidney Disease Act
Client: TRAVERE THERAPEUTICS · Firm: TRAVERE THERAPEUTICS
Legislation regarding the Orphan Drug Act and rare disease diagnosis, treatment, and care. Legislation regarding kidney disease and in particular rare kidney disease. HR 6790, the New Era of Preventing End-Stage Kidney Disease Act
Creating Hope Reauthorization Act of 2024
Client: TRAVERE THERAPEUTICS · Firm: TRAVERE THERAPEUTICS
Legislation regarding FDA and clinical research, particularly with respect to rare disease and orphan drug development and the accelerated approval pathway, and related legislation regarding FY 2024 Appropriations. FY 2025 appropriations for CDC newborn screening programs. HR 7384/S. 4583, Creating Hope Reauthorization Act to renew PRV program.
Creating Hope Reauthorization Act of 2024
Client: TRAVERE THERAPEUTICS · Firm: TRAVERE THERAPEUTICS
Legislation regarding FDA and clinical research, particularly with respect to rare disease and orphan drug development and the accelerated approval pathway, and related legislation regarding FY 2024 Appropriations. FY 2025 appropriations for CDC newborn screening programs. HR 7384/S. 4583, Creating Hope Reauthorization Act to renew PRV program.
HR 1262, S 932 Give Kids a Chance Act to renew PRV program; related provisions in H.R.1, One Big Beautiful Bill Act; HR 4709, the Newborn Screening Saves Lives Reauthorization Act; PDUFA/regulatory review process; H.R. 9102, Biotech Investment National Security Act (BINSA); H.R. 10359, Priority for Pediatric Cures Act to make PRV permanent
HR 946 and S. 1862, Optimizing Research Progress Hope and New Cures (ORPHAN Cures Act); related provisions in H.R.1, One Big Beautiful Bill Act; Most Favored Nation and international reference pricing proposals
H.R. 1414, Cameron's Law to increase Orphan Drug Tax Credit to 50%; R&D tax credit; related implementation provisions in H.R.1, One Big Beautiful Bill Act; pharmaceutical tariffs, specifically related to orphan drugs
Regulations regarding transparency, reimbursement and care, particularly regarding rare disease. Medicare and Medicaid related provisions in H.R.1, One Big Beautiful Bill Act.H.R. 9509, the Kidney Disease Education Expansion Act
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
TRAVERE THERAPEUTICS via TRAVERE THERAPEUTICS
2026 · second_quarter · Q2
S.1040, to prohibit product hopping and for other purposes; proposals regarding patent thickets. S. 2658, Medication Affordability and Patent Integrity Act
HR 1262, S 932 Give Kids a Chance Act to renew PRV program; related provisions in H.R.1, One Big Beautiful Bill Act; HR 4709, the Newborn Screening Saves Lives Reauthorization Act; PDUFA/regulatory review process; H.R. 9102, Biotech Investment National Security Act (BINSA)
Regulations regarding transparency, reimbursement and care, particularly regarding rare disease. Medicare and Medicaid related provisions in H.R.1, One Big Beautiful Bill Act.H.R. 9509, the Kidney Disease Education Expansion Act
H.R. 1414, Cameron's Law to increase Orphan Drug Tax Credit to 50%; R&D tax credit; related implementation provisions in H.R.1, One Big Beautiful Bill Act; pharmaceutical tariffs, specifically related to orphan drugs
Legislation regarding the Orphan Drug Act and rare disease diagnosis, treatment, and care. Legislation regarding kidney disease and in particular rare kidney disease. HR 1518, the New Era of Preventing End-Stage Kidney Disease Act; end-stage renal disease policy and rare kidney disease
HR 946 and S. 1862, Optimizing Research Progress Hope and New Cures (ORPHAN Cures Act); related provisions in H.R.1, One Big Beautiful Bill Act; Most Favored Nation and international reference pricing proposals
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
TRAVERE THERAPEUTICS via TRAVERE THERAPEUTICS
2026 · first_quarter · Q1
Legislation regarding the Orphan Drug Act and rare disease diagnosis, treatment, and care. Legislation regarding kidney disease and in particular rare kidney disease. HR 1518, the New Era of Preventing End-Stage Kidney Disease Act; end-stage renal disease policy and rare kidney disease
Regulations regarding transparency, reimbursement and care, particularly regarding rare disease. Medicare and Medicaid related provisions in H.R.1, One Big Beautiful Bill Act.
HR 1262, S 932 Give Kids a Chance Act to renew PRV program; related provisions in H.R.1, One Big Beautiful Bill Act; HR 4709, the Newborn Screening Reauthorization Act; PDUFA/regulatory review process
HR 946 and S. 1862, Optimizing Research Progress Hope and New Cures (ORPHAN Cures Act); related provisions in H.R.1, One Big Beautiful Bill Act; Most Favored Nation and international reference pricing proposals
H.R. 1414, Cameron's Law to increase Orphan Drug Tax Credit to 50%; R&D tax credit; related implementation provisions in H.R.1, One Big Beautiful Bill Act; tariffs
S.1040, to prohibit product hopping and for other purposes; proposals regarding patent thickets
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
TRAVERE THERAPEUTICS via TRAVERE THERAPEUTICS
2025 · fourth_quarter · Q4
Legislation regarding the Orphan Drug Act and rare disease diagnosis, treatment, and care. Legislation regarding kidney disease and in particular rare kidney disease. HR 1518, the New Era of Preventing End-Stage Kidney Disease Act
HR 946 and S. 1862, Optimizing Research Progress Hope and New Cures (ORPHAN Cures Act); related provisions in H.R.1, One Big Beautiful Bill Act; Most Favored Nation and international reference pricing proposals
HR 1262, S 932 Give Kids a Chance Act to renew PRV program; related provisions in H.R.1, One Big Beautiful Bill Act; HR 4709, the Newborn Screening Reauthorization Act
Regulations regarding transparency, reimbursement and care, particularly regarding rare disease. Medicare and Medicaid related provisions in H.R.1, One Big Beautiful Bill Act.
S.1040, to prohibit product hopping and for other purposes; proposals regarding patent thickets
H.R. 1414, Cameron's Law to increase Orphan Drug Tax Credit to 50%; R&D tax credit; related provisions in H.R.1, One Big Beautiful Bill Act; tariffs
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
TRAVERE THERAPEUTICS via TRAVERE THERAPEUTICS
2025 · third_quarter · Q3
Legislation regarding the Orphan Drug Act and rare disease diagnosis, treatment, and care. Legislation regarding kidney disease and in particular rare kidney disease. HR 1518, the New Era of Preventing End-Stage Kidney Disease Act
HR 946 and S. 1862, Optimizing Research Progress Hope and New Cures (ORPHAN Cures Act); related provisions in H.R.1, One Big Beautiful Bill Act; Most Favored Nation and international reference pricing proposals
HR 1262, S 932 Give Kids a Chance Act to renew PRV program; related provisions in H.R.1, One Big Beautiful Bill Act; HR 4709, the Newborn Screening Reauthorization Act
Regulations regarding transparency, reimbursement and care, particularly regarding rare disease. Medicare and Medicaid related provisions in H.R.1, One Big Beautiful Bill Act.
S.1040, to prohibit product hopping and for other purposes
H.R. 1414, Cameron's Law to increase Orphan Drug Tax Credit to 50%; R&D tax credit; related provisions in H.R.1, One Big Beautiful Bill Act; tariffs
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
TRAVERE THERAPEUTICS via TRAVERE THERAPEUTICS
2025 · second_quarter · Q2
Legislation regarding the Orphan Drug Act and rare disease diagnosis, treatment, and care. Legislation regarding kidney disease and in particular rare kidney disease. HR 1518, the New Era of Preventing End-Stage Kidney Disease Act
HR 946 and S. 1862, Optimizing Research Progress Hope and New Cures (ORPHAN Cures Act); related provisions in H.R.1, One Big Beautiful Bill Act; Most Favored Nation and international reference pricing proposals
HR 1262, S 932 Give Kids a Chance Act to renew PRV program; related provisions in H.R.1, One Big Beautiful Bill Act
TRAVERE THERAPEUTICS via TRAVERE THERAPEUTICS
2025 · first_quarter · Q1
Legislation regarding the Orphan Drug Act and rare disease diagnosis, treatment, and care. Legislation regarding kidney disease and in particular rare kidney disease. HR 1518, the New Era of Preventing End-Stage Kidney Disease Act
HR 946, Optimizing Research Progress Hope and New Cures (ORPHAN Cures Act)
HR 1262, S 932 Give Kids a Chance Act to renew PRV program
TRAVERE THERAPEUTICS via TRAVERE THERAPEUTICS
2024 · fourth_quarter · Q4
S. 150/H.R. 9070, the Affordable Prescriptions for Patients Act of 2023, and related House legislation.
Legislation regarding FDA and clinical research, particularly with respect to rare disease and orphan drug development and the accelerated approval pathway, and related legislation regarding FY 2024 Appropriations. FY 2025 appropriations for CDC newborn screening programs. HR 7384/S. 4583, Creating Hope Reauthorization Act to renew PRV program. HR 10445, the Continuing Resolution and provisions related to the PRV program.
Legislation impacting products approved under the Accelerated Approval pathway, including the Accelerating Clinical Evidence demonstration project. Regulations regarding transparency, reimbursement and care, particularly regarding rare disease. Legislation regarding implementation of the Food and Drug Omnibus Reform Act of 2022.
TRAVERE THERAPEUTICS via TRAVERE THERAPEUTICS
2024 · third_quarter · Q3
S. 150/H.R. 9070, the Affordable Prescriptions for Patients Act of 2023, and related House legislation and issues.
Legislation regarding the Orphan Drug Act and rare disease diagnosis, treatment, and care. Legislation regarding kidney disease and in particular rare kidney disease. HR 6790, the New Era of Preventing End-Stage Kidney Disease Act
Legislation impacting products approved under the Accelerated Approval pathway, including the Accelerating Clinical Evidence demonstration project. Regulations regarding transparency, reimbursement and care, particularly regarding rare disease. Legislation regarding implementation of the Food and Drug Omnibus Reform Act of 2022.
TRAVERE THERAPEUTICS via TRAVERE THERAPEUTICS
2024 · second_quarter · Q2
Legislation regarding FDA and clinical research, particularly with respect to rare disease and orphan drug development and the accelerated approval pathway, and related legislation regarding FY 2024 Appropriations. FY 2025 appropriations for CDC newborn screening programs. HR 7384/S. 4583, Creating Hope Reauthorization Act to renew PRV program.
Legislation impacting products approved under the Accelerated Approval pathway, including the Accelerating Clinical Evidence demonstration project. Regulations regarding transparency, reimbursement and care, particularly regarding rare disease. Legislation regarding implementation of the Food and Drug Omnibus Reform Act of 2022.
TRAVERE THERAPEUTICS via TRAVERE THERAPEUTICS
2024 · first_quarter · Q1
S. 150, the Affordable Prescriptions for Patients Act of 2023, and related House legislation and issues.
Legislation regarding FDA and clinical research, particularly with respect to rare disease and orphan drug development and the accelerated approval pathway, and related legislation regarding FY 2024 Appropriations. FY 2025 appropriations for CDC newborn screening resources.
Legislation regarding the Orphan Drug Tax Credit. H.R. 1350, Cameron's Law. H.R. 1805, Leo's Law.
TRAVERE THERAPEUTICS via TRAVERE THERAPEUTICS
2023 · fourth_quarter · Q4
Legislation regarding the Orphan Drug Act and rare disease diagnosis, treatment, and care. Legislation regarding kidney disease and in particular rare kidney disease. HR 6790, the New Era of Preventing End-Stage Kidney Disease Act
Legislation impacting products approved under the Accelerated Approval pathway, including the Accelerating Clinical Evidence demonstration project. Legislation regarding implementation of the Food and Drug Omnibus Reform Act of 2022.
Legislation regarding drug pricing, value, and reimbursement including implementation of the Inflation Reduction Act of 2022. The Safe Step Act, H.R. 2630/S. 652. The HELP Copays Act, H.R. 830/S. 1375. H.R. 5339/S 3131, the Optimizing Research Progress Hope and New Cures (ORPHAN Cures Act).
TRAVERE THERAPEUTICS via TRAVERE THERAPEUTICS
2023 · third_quarter · Q3
Legislation impacting products approved under the Accelerated Approval pathway, including the Accelerating Clinical Evidence demonstration project. Legislation regarding implementation of the Food and Drug Omnibus Reform Act of 2022.
Legislation regarding drug pricing, value, and reimbursement including implementation of the Inflation Reduction Act of 2022. The Safe Step Act, H.R. 2630/S. 652. The HELP Copays Act, H.R. 830/S. 1375. H.R. 5339, the Optimizing Research Progress Hope and New Cures (ORPHAN Cures Act).
S. 150, the Affordable Prescriptions for Patients Act of 2023, and related House legislation and issues.
TRAVERE THERAPEUTICS via TRAVERE THERAPEUTICS
2023 · second_quarter · Q2
Legislation impacting products approved under the Accelerated Approval pathway. Legislation regarding implementation of the Food and Drug Omnibus Reform Act of 2022.
Legislation regarding the Orphan Drug Act and rare disease diagnosis, treatment, and care. Legislation regarding newborn screening and related FY 2024 CDC appropriations. Legislation regarding kidney disease and in particular rare kidney disease.
Legislation regarding FDA and clinical research, particularly with respect to rare disease and orphan drug development and the accelerated approval pathway, and related legislation regarding FY 2024 Appropriations. FY 2024 appropriations for CDC newborn screening resources.
TRAVERE THERAPEUTICS via TRAVERE THERAPEUTICS
2023 · first_quarter · Q1
Legislation impacting products approved under the Accelerated Approval pathway.
Legislation regarding FDA and clinical research, particularly with respect to rare disease and orphan drug development and the accelerated approval pathway.
Legislation regarding drug pricing, value, and reimbursement including implementation of the Inflation Reduction Act of 2022
TRAVERE THERAPEUTICS via TRAVERE THERAPEUTICS
2022 · fourth_quarter · RA
Issues related to rare disease research, detection, diagnosis, treatment, care, and reimbursement.
TRAVERE THERAPEUTICS via TRAVERE THERAPEUTICS
2022 · fourth_quarter · Q4
H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act and related Senate legislation. H.R. 19, Lower Costs More Cures Act. Legislative proposals regarding drug pricing, value, and reimbursement in H.R. 5376 Build Back Better Act/Inflation Reduction Act. H.R. 7667, the Food and Drug Amendments of 2022 and related Senate legislation. H.R.2471, Consolidated Appropriations Act, 2022 including the Food and Drug Omnibus Reform Act.
Provisions of H.R. 5736 Build Back Better Act and Inflation Reduction Act regarding the Orphan Drug Tax Credit; related rare disease research incentives. Legislation regarding tax treatment of net operating losses.
TRAVERE THERAPEUTICS via TRAVERE THERAPEUTICS
2022 · third_quarter · Q3
S.1435 - Affordable Prescriptions for Patients Act of 2021, H.R.2873 Affordable Prescriptions for Patients Through Promoting Competition Act of 2021, and H.R.2884, Affordable Prescriptions for Patients Through Improvements to Patent Litigation Act; other 1egislation regarding intellectual property and trademark issues, including waivers of international trade agreements.
Provisions of H.R. 5736 Build Back Better Act and Inflation Reduction Act regarding the Orphan Drug Tax Credit; related rare disease research incentives. Legislation regarding tax treatment of net operating losses.
TRAVERE THERAPEUTICS via TRAVERE THERAPEUTICS
2022 · second_quarter · Q2
H.R. 1730, S. 670, Speeding Therapy Access Today Act of 2021; H.R. 3893, Coordination, Accountability, Research, and Equity for All Kidneys Act of 2021. Congressional consideration of the Prescription Drug User Fee Act. H.R. 6963, Accelerated Approval Integrity Act, and H.R. 6996, Accelerated Access for Patient Act, and Senate proposals regarding expedited FDA pathways. H.R. 7506, the New Era of Preventing End-Stage Kidney Disease
H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act and related Senate legislation. H.R. 19, Lower Costs More Cures Act. Legislative proposals regarding drug pricing, value, and reimbursement in H.R. 5736 Build Back Better Act and related Senate legislation. H.R. 7667, the Food and Drug Amendments of 2022 and related Senate legislation.
TRAVERE THERAPEUTICS via TRAVERE THERAPEUTICS
2022 · first_quarter · Q1
Provisions of H.R. 5736 Build Back Better Act and related Senate legislation regarding the Orphan Drug Tax Credit; related rare disease research incentives. Legislation regarding tax treatment of net operating losses.
H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act and related Senate legislation. H.R. 19, Lower Costs More Cures Act. Legislative proposals regarding drug pricing, value, and reimbursement in H.R. 5736 Build Back Better Act and related Senate legislation.
S.1435 - Affordable Prescriptions for Patients Act of 2021, H.R.2873 Affordable Prescriptions for Patients Through Promoting Competition Act of 2021, and H.R.2884, Affordable Prescriptions for Patients Through Improvements to Patent Litigation Act; other 1egislation regarding intellectual property and trademark issues, including waivers of international trade agreements.
TRAVERE THERAPEUTICS via TRAVERE THERAPEUTICS
2021 · fourth_quarter · Q4
H.R. 2873, the Affordable Prescriptions for Patients Through Promoting Competition Act of 2021; other 1egislation regarding intellectual property and trademark issues, including waivers of international trade agreements.
H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act and related Senate legislation. H.R. 19, Lower Costs More Cures Act. Legislative proposals regarding drug pricing, value, and reimbursement in H.R. 5736 Build Back Better Act and related Senate legislation.
H.R. 1730, S. 670, Speeding Therapy Access Today Act of 2021; legislation regarding diagnosis and treatment of rare kidney diseases
TRAVERE THERAPEUTICS via TRAVERE THERAPEUTICS
2021 · third_quarter · Q3
Legislative proposals regarding drug pricing, value, and reimbursement. H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act and related Senate legislation. H.R. 19, Lower Costs More Cures Act
Provisions of House Ways and Means Build Back Better legislation regarding the Orphan Drug Tax Credit; related rare disease research incentives. Legislation regarding tax treatment of net operating losses.
H.R. 2873, the Affordable Prescriptions for Patients Through Promoting Competition Act of 2021; other 1egislation regarding intellectual property and trademark issues, including waivers of international trade agreements.
TRAVERE THERAPEUTICS via TRAVERE THERAPEUTICS
2021 · second_quarter · Q2
H.R. 1730, S. 670, Speeding Therapy Access Today Act of 2021; legislation regarding diagnosis and treatment of rare kidney diseases
Legislation regarding intellectual property and trademark issues, including waivers of international trade agreements.
HR 366, Protecting Access to Post-COVID-19 Telehealth Act; other legislative proposals to ensure access to telehealth services
TRAVERE THERAPEUTICS via TRAVERE THERAPEUTICS
2021 · first_quarter · Q1
Legislative proposals regarding drug pricing, value, and reimbursement.
H.R. 1730, S. 670, Speeding Therapy Access Today Act of 2021; legislation regarding diagnosis and treatment of rare kidney diseases
Legislation regarding the Orphan Drug Act and rare disease diagnosis, treatment, and care. Newborn Screening Saves Lives Act Reauthorization, H.R. 482, S 350. FY 2022 CDC Appropriations for state newborn screening technical assistance.
TRAVERE THERAPEUTICS via TRAVERE THERAPEUTICS
2020 · fourth_quarter · Q4
H.R. 1781, Payment Commission Data Act; H.R. 1503, Orange Book Transparency Act of 2019; H.R. 1520, Purple Book Continuity Act of 2019; H.R. 965 and S. 340, the CREATES Act; H.R. 2113, STAR Act; S. 474, SPIKE Act/Wyden; S. 1391, FAIR Drug Pricing Act; S. 1895, Lower Health Care Costs Act of 2019; H.R. 2296, FAIR/More Efficient Tools to Realize Information for Consumers Act; H.R. 987, Strengthening Health Care and Lowering Prescription Drug Costs Act; H.R. 3, Lower Drug Costs Now Act; H.R. 19, Lower Costs More Cures Act and related legislation; S. 2543, Prescription Drug Pricing Reduction Act
Medical research, NIH funding, related appropriations issues; House and Senate Labor HHS Appropriations Act; FY 2021 CDC Appropriations related to newborn screening; H.R. 478, CARES Act; H.R. 6800, HEROES Act; kidney treatment and care issues; HR 133, Consolidated Appropriations Act of 2021
TRAVERE THERAPEUTICS via TRAVERE THERAPEUTICS
2020 · third_quarter · Q3
H.R. 990 and S. 344, the Hatch-Waxman Integrity Act; S. 1416, Affordable Prescriptions for Patients Act of 2019: H.R. 3991, Affordable Prescriptions for Patients Through Improvements to Patent Litigation Act of 2019; H.R. 4398, Affordable Prescriptions for Patients Through Promoting Competition Act of 2019; Senate amendment to H.R. 2486
H.R. 1046, Medicare Price Negotiation and Competitive Licensing Act; FY 2021 Medicare and Medicaid proposals, including proposed International Pricing Index; H.R. 7078, Evaluating Disparities and Outcomes of Telehealth During the COVID-19 Emergency Act of 2020; H.R.7663, Protecting Access to Post-COVID-19 Telehealth Act of 2020; other telehealth issues
TRAVERE THERAPEUTICS via TRAVERE THERAPEUTICS
2020 · second_quarter · Q2
H.R. 1781, Payment Commission Data Act; H.R. 1503, Orange Book Transparency Act of 2019; H.R. 1520, Purple Book Continuity Act of 2019; H.R. 965 and S. 340, the CREATES Act; H.R. 2113, STAR Act; S. 474, SPIKE Act/Wyden; S. 1391, FAIR Drug Pricing Act; S. 1895, Lower Health Care Costs Act of 2019; H.R. 2296, FAIR/More Efficient Tools to Realize Information for Consumers Act; H.R. 987, Strengthening Health Care and Lowering Prescription Drug Costs Act; H.R. 3, Lower Drug Costs Now Act; H.R. 19, Lower Costs More Cures Act and related legislation
H.R. 990 and S. 344, the Hatch-Waxman Integrity Act; S. 1416, Affordable Prescriptions for Patients Act of 2019: H.R. 3991, Affordable Prescriptions for Patients Through Improvements to Patent Litigation Act of 2019; H.R. 4398, Affordable Prescriptions for Patients Through Promoting Competition Act of 2019; Senate amendment to H.R. 2486
TRAVERE THERAPEUTICS via TRAVERE THERAPEUTICS
2020 · first_quarter · Q1
H.R. 1046, Medicare Price Negotiation and Competitive Licensing Act; FY 2021 Medicare and Medicaid proposals, including proposed International Pricing Index
Medical research, NIH funding, related appropriations issues; Senate Labor HHS Appropriations Act; FY 2021 CDC Appropriations
Rare disease patient care, screening, and coverage issues in authorization and appropriations legislation; Orphan Drug Act; H.R. 2507, S. 2158 Newborn Screening Saves Lives Act Reauthorization; FY 2022 CDC Appropriations; HR 4144, Ending the Diagnostic Odyssey Act; H.R. 5062, Advancing Access to Precision Medicine Act; H.R. 4712, S. 3271 Fairness in Orphan Drug Exclusivity Act; H.R. 534, Aidan's Law
TRAVERE THERAPEUTICS via TRAVERE THERAPEUTICS
2019 · fourth_quarter · Q4
H.R. 1046, Medicare Price Negotiation and Competitive Licensing Act; FY 2020 Medicare and Medicaid proposals, including proposed International Pricing Index
H.R. 990 and S. 344, the Hatch-Waxman Integrity Act; S. 1416, Affordable Prescriptions for Patients Act of 2019: H.R. 3991, Affordable Prescriptions for Patients Through Improvements to Patent Litigation Act of 2019; H.R. 4398, Affordable Prescriptions for Patients Through Promoting Competition Act of 2019
Rare disease patient care, screening, and coverage issues in authorization and appropriations legislation; Orphan Drug Act; HRes 242, Affirming importance of Orphan Drug Act; H.R. 2507, S. 2158 Newborn Screening Saves Lives Act Reauthorization; HR 4144, Ending the Diagnostic Odyssey Act; H.R. 5062, Advancing Access to Precision Medicine Act; H.R. 4712, Fairness in Orphan Drug Exclusivity Act
TRAVERE THERAPEUTICS via TRAVERE THERAPEUTICS
2019 · third_quarter · Q3
Medical research, NIH funding, related appropriations issues; Senate Labor HHS Appropriations Act
H.R. 990 and S. 344, the Hatch-Waxman Integrity Act; S. 1416, Affordable Prescriptions for Patients Act of 2019: H.R. 3991, Affordable Prescriptions for Patients Through Improvements to Patent Litigation Act of 2019; H.R. 4398, Affordable Prescriptions for Patients Through Promoting Competition Act of 2019
Rare disease patient care, screening, and coverage issues in authorization and appropriations legislation; Orphan Drug Act; HRes 242, Affirming importance of Orphan Drug Act; H.R. 2507, S. 2158 Newborn Screening Saves Lives Act Reauthorization; HR 4144, Ending the Diagnostic Odyssey Act
TRAVERE THERAPEUTICS via TRAVERE THERAPEUTICS
2019 · second_quarter · Q2
Rare disease patient care, screening, and coverage issues in authorization and appropriations legislation; Orphan Drug Act; HRes 242, Affirming importance of Orphan Drug Act; H.R. 2507, Newborn Screening Saves Lives Act Reauthorization
Medical research, NIH funding, related appropriations issues
H.R. 1046, Medicare Price Negotiation and Competitive Licensing Act; FY 2020 Medicare and Medicaid proposals, including proposed International Pricing Index
TRAVERE THERAPEUTICS via TRAVERE THERAPEUTICS
2019 · first_quarter · Q1
Issues related to the Orphan Drug Tax Credit
H.R. 1046, Medicare Price Negotiation and Competitive Licensing Act; FY 2020 Medicare and Medicaid proposals, including proposed International Pricing Index
H.R. 990 and S. 344, the Hatch-Waxman Integrity Act
TRAVERE THERAPEUTICS via TRAVERE THERAPEUTICS
2018 · fourth_quarter · Q4
Intellectual property issues and commercial litigation, including S. 1390 and H.R. 5390, STRONGER Patents Act
Tax legislation relating to the Orphan Drug Tax Credit, development, and rare disease patient issues; implementation of HR 1, the Tax Cuts and Jobs Act.
Medical research, NIH funding, related appropriations issues
TRAVERE THERAPEUTICS via TRAVERE THERAPEUTICS
2018 · third_quarter · Q3
Rare disease patient care, screening, and coverage issues in authorization and appropriations legislation, S 1151 Credit for Caring Act
Orphan Drug Act, Drug Quality and Security Act drug safety issues, drug pricing, opioid legislation provisions related to opioid sparing, FAST Generics and CREATES Acts, FDA issues
FY 2019 budget proposals with respect to Medicare and Medicaid reform
TRAVERE THERAPEUTICS via TRAVERE THERAPEUTICS
2018 · second_quarter · Q2
Rare disease patient care, screening, and coverage issues in authorization and appropriations legislation, S 1151 Credit for Caring Act
FY 2019 budget proposals with respect to Medicare and Medicaid reform
Orphan Drug Act, Drug Quality and Security Act drug safety issues, drug pricing, opioid legislation, FAST Generics and CREATES Acts, FDA issues
TRAVERE THERAPEUTICS via TRAVERE THERAPEUTICS
2018 · first_quarter · Q1
Tax legislation relating to the Orphan Drug Tax Credit, development, and rare disease patient issues; implementation of HR 1, the Tax Cuts and Jobs Act.
Intellectual property issues and commercial litigation, including S. 1390 and H.R. 5390, STRONGER Patents Act
Medical research, NIH funding, related appropriations issues
TRAVERE THERAPEUTICS via TRAVERE THERAPEUTICS
2017 · fourth_quarter · Q4
American Health Care Act and Better Care Reconciliation Act Medicaid provisions.
Rare disease patient care, screening, and coverage issues in American Health Care Act and Better Care Reconciliation Act
Medical research, NIH funding, related appropriations issues
TRAVERE THERAPEUTICS via TRAVERE THERAPEUTICS
2017 · third_quarter · Q3
Medical research, NIH funding, related appropriations issues
Rare disease patient care, screening, and coverage issues in American Health Care Act and Better Care Reconciliation Act
Orphan Drug Act, Drug Quality and Security Act drug safety issues, drug pricing, Prescription Drug User Fee Act reauthorization, FAST Generics and CREATES Acts, FDA issues
TRAVERE THERAPEUTICS via TRAVERE THERAPEUTICS
2017 · second_quarter · 2A
Orphan Drug Act, Drug Quality and Security Act drug safety issues, drug pricing, Prescription Drug User Fee Act reauthorization, FAST Generics and CREATES Acts, FDA issues
Medical research, NIH funding, FDA personnel issues
Intellectual property issues and commercial litigation
TRAVERE THERAPEUTICS via TRAVERE THERAPEUTICS
2017 · second_quarter · Q2
American Health Care Act Medicaid provisions.
Medical research, NIH funding, FDA personnel issues
Rare disease patient care, screening, and coverage issues in American Health Care Act and Better Care Reconciliation Act
TRAVERE THERAPEUTICS via TRAVERE THERAPEUTICS
2017 · first_quarter · Q1
Medical research, NIH funding, FDA personnel issues
American Health Care Act
Rare disease patient care and screening
TRAVERE THERAPEUTICS via TRAVERE THERAPEUTICS
2016 · third_quarter · RA
Rare disease patient care and screening issues
Rare disease patient care and screening issues
TRAVERE THERAPEUTICS via TRAVERE THERAPEUTICS
2016 · fourth_quarter · Q4
Rare disease patient care and screening issues
Orphan Drug Act; Drug Quality and Security Act, proposed revisions and implementation; drug pricing; HR 6, 21st Century Cures and related Senate legislation; intellectual property
HR 6, 21st Century Cures Act and related Senate legislation
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
TRAVERE THERAPEUTICS via TRAVERE THERAPEUTICS
2016 · third_quarter · 3A
HR 6, 21st Century Cures Act and related Senate legislation
Orphan Drug Act; Drug Quality and Security Act, proposed revisions and implementation; drug pricing; HR 6, 21st Century Cures and related Senate legislation; intellectual property
Rare disease patient care and screening issues
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
TRAVERE THERAPEUTICS via TRAVERE THERAPEUTICS
2016 · third_quarter · RR
HR 6, 21st Century Cures Act and related Senate legislation Orphan Drug Act and related issues Drug Quality and Security Act, proposed revisions and implementation Rare diseases patient care and screening issues Intellectual property Drug pricing
HR 6, 21st Century Cures Act and related Senate legislation Orphan Drug Act and related issues Drug Quality and Security Act, proposed revisions and implementation Rare diseases patient care and screening issues Intellectual property Drug pricing
HR 6, 21st Century Cures Act and related Senate legislation Orphan Drug Act and related issues Drug Quality and Security Act, proposed revisions and implementation Rare diseases patient care and screening issues Intellectual property Drug pricing
Regulations regarding transparency, reimbursement and care, particularly regarding rare disease. Medicare and Medicaid related provisions in H.R.1, One Big Beautiful Bill Act.
S.1040, to prohibit product hopping and for other purposes
H.R. 1414, Cameron's Law to increase Orphan Drug Tax Credit to 50%; R&D tax credit; related provisions in H.R.1, One Big Beautiful Bill Act; tariffs
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Regulations regarding transparency, reimbursement and care, particularly regarding rare disease.
S.1040, to prohibit product hopping and for other purposes
H.R. 1414, Cameron's Law to increase Orphan Drug Tax Credit to 50%
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Legislation regarding the Orphan Drug Tax Credit. H.R. 1350, Cameron's Law. H.R. 1805, Leo's Law.
Legislation regarding the Orphan Drug Act and rare disease diagnosis, treatment, and care. Legislation regarding kidney disease and in particular rare kidney disease. HR 6790, the New Era of Preventing End-Stage Kidney Disease Act
Legislation regarding drug pricing, value, and reimbursement including implementation of the Inflation Reduction Act of 2022. The Safe Step Act, H.R. 2630/S. 652. The HELP Copays Act, H.R. 830/S. 1375. H.R. 5339/S 3131, the Optimizing Research Progress Hope and New Cures (ORPHAN Cures Act).
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Legislation regarding FDA and clinical research, particularly with respect to rare disease and orphan drug development and the accelerated approval pathway, and related legislation regarding FY 2024 Appropriations. FY 2025 appropriations for CDC newborn screening programs. HR 7384/S. 4583, Creating Hope Reauthorization Act to renew PRV program.
Legislation regarding drug pricing, value, and reimbursement including implementation of the Inflation Reduction Act of 2022. The Safe Step Act, H.R. 2630/S. 652. The HELP Copays Act, H.R. 830/S. 1375. H.R. 5339/S 3131, the Optimizing Research Progress Hope and New Cures (ORPHAN Cures Act).
Legislation regarding the Orphan Drug Tax Credit. H.R. 1350, Cameron's Law. H.R. 1805, Leo's Law.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Legislation regarding drug pricing, value, and reimbursement including implementation of the Inflation Reduction Act of 2022. The Safe Step Act, H.R. 2630/S. 652. The HELP Copays Act, H.R. 830/S. 1375. H.R. 5339/S 3131, the Optimizing Research Progress Hope and New Cures (ORPHAN Cures Act).
Legislation regarding the Orphan Drug Tax Credit. H.R. 1350, Cameron's Law. H.R. 1805, Leo's Law.
Legislation regarding the Orphan Drug Act and rare disease diagnosis, treatment, and care. Legislation regarding kidney disease and in particular rare kidney disease. HR 6790, the New Era of Preventing End-Stage Kidney Disease Act
S. 150, the Affordable Prescriptions for Patients Act of 2023, and related House legislation and issues.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Legislation regarding drug pricing, value, and reimbursement including implementation of the Inflation Reduction Act of 2022. The Safe Step Act, H.R. 2630/S. 652. The HELP Copays Act, H.R. 830/S. 1375. H.R. 5339/S 3131, the Optimizing Research Progress Hope and New Cures (ORPHAN Cures Act).
Legislation regarding the Orphan Drug Act and rare disease diagnosis, treatment, and care. Legislation regarding kidney disease and in particular rare kidney disease. HR 6790, the New Era of Preventing End-Stage Kidney Disease Act
Legislation impacting products approved under the Accelerated Approval pathway, including the Accelerating Clinical Evidence demonstration project. Regulations regarding transparency, reimbursement and care, particularly regarding rare disease. Legislation regarding implementation of the Food and Drug Omnibus Reform Act of 2022.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Legislation regarding the Orphan Drug Tax Credit. H.R. 1350, Cameron's Law. H.R. 1805, Leo's Law.
Legislation regarding FDA and clinical research, particularly with respect to rare disease and orphan drug development and the accelerated approval pathway, and related legislation regarding FY 2024 Appropriations. FY 2024 appropriations for CDC newborn screening resources.
S. 150, the Affordable Prescriptions for Patients Act of 2023, and related House legislation and issues.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Legislation regarding FDA and clinical research, particularly with respect to rare disease and orphan drug development and the accelerated approval pathway, and related legislation regarding FY 2024 Appropriations. FY 2024 appropriations for CDC newborn screening resources.
Legislation regarding the Orphan Drug Tax Credit. H.R. 1350, Cameron's Law. H.R. 1805, Leo's Law.
Legislation regarding the Orphan Drug Act and rare disease diagnosis, treatment, and care. Legislation regarding kidney disease and in particular rare kidney disease.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
S. 150, the Affordable Prescriptions for Patients Act of 2023, and related House legislation and issues.
Legislation regarding the Orphan Drug Tax Credit. H.R. 1350, Cameron's Law. H.R. 1805, Leo's Law.
Legislation regarding drug pricing, value, and reimbursement including implementation of the Inflation Reduction Act of 2022. Legislation regarding the Orphan Drug Exemption within the Inflation Reduction Act of 2022. The Safe Step Act, H.R. 2630/S. 652. The HELP Copays Act, H.R. 830/S. 1375.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Legislation regarding the Orphan Drug Act and rare disease diagnosis, treatment, and care. Legislation regarding newborn screening and related FY 2024 CDC appropriations. Legislation regarding kidney disease and in particular rare kidney disease.
Legislation regarding the Orphan Drug Tax Credit; H.R. 1350, Cameron's Law
S. 150, the Affordable Prescriptions for Patients Act of 2023 and related issues.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
HR 366, Protecting Access to Post-COVID-19 Telehealth Act; other legislative proposals to ensure access to telehealth services. H.R.2471, Consolidated Appropriations Act, 2022 including health provisions and the Food and Drug Omnibus Reform Act.
Legislation regarding the Orphan Drug Act and rare disease diagnosis, treatment, and care. Newborn Screening Saves Lives Act Reauthorization, H.R. 482, S 350. FY 2022 and FY 2023 CDC Appropriations for state newborn screening technical assistance and related Senate appropriations. H.R. 1692, S 250, Fairness in Orphan Drug Exclusivity Act.
H.R. 1730, S. 670, Speeding Therapy Access Today Act of 2021; H.R. 3893, Coordination, Accountability, Research, and Equity for All Kidneys Act of 2021. Congressional consideration of the Prescription Drug User Fee Act. H.R. 6963, Accelerated Approval Integrity Act, and H.R. 6996, Accelerated Access for Patient Act, and Senate proposals regarding expedited FDA pathways. H.R. 7506, the New Era of Preventing End-Stage Kidney Disease. H.R.2471, Consolidated Appropriations Act, 2022.
S.1435 - Affordable Prescriptions for Patients Act of 2021, H.R.2873 Affordable Prescriptions for Patients Through Promoting Competition Act of 2021, and H.R.2884, Affordable Prescriptions for Patients Through Improvements to Patent Litigation Act; other 1egislation regarding intellectual property and trademark issues, including waivers of international trade agreements.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
HR 366, Protecting Access to Post-COVID-19 Telehealth Act; other legislative proposals to ensure access to telehealth services
H.R. 1730, S. 670, Speeding Therapy Access Today Act of 2021; H.R. 3893, Coordination, Accountability, Research, and Equity for All Kidneys Act of 2021. Congressional consideration of the Prescription Drug User Fee Act. H.R. 6963, Accelerated Approval Integrity Act, and H.R. 6996, Accelerated Access for Patient Act, and Senate proposals regarding expedited FDA pathways. H.R. 7506, the New Era of Preventing End-Stage Kidney Disease.
Legislation regarding the Orphan Drug Act and rare disease diagnosis, treatment, and care. Newborn Screening Saves Lives Act Reauthorization, H.R. 482, S 350. FY 2022 and FY 2023 CDC Appropriations for state newborn screening technical assistance and related Senate appropriations. H.R. 1692, S 250, Fairness in Orphan Drug Exclusivity Act.
H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act and related Senate legislation. H.R. 19, Lower Costs More Cures Act. Legislative proposals regarding drug pricing, value, and reimbursement in H.R. 5376 Build Back Better Act/Inflation Reduction Act. H.R. 7667, the Food and Drug Amendments of 2022 and related Senate legislation.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
S.1435 - Affordable Prescriptions for Patients Act of 2021, H.R.2873 Affordable Prescriptions for Patients Through Promoting Competition Act of 2021, and H.R.2884, Affordable Prescriptions for Patients Through Improvements to Patent Litigation Act; other 1egislation regarding intellectual property and trademark issues, including waivers of international trade agreements.
HR 366, Protecting Access to Post-COVID-19 Telehealth Act; other legislative proposals to ensure access to telehealth services
Provisions of H.R. 5736 Build Back Better Act and related Senate legislation regarding the Orphan Drug Tax Credit; related rare disease research incentives. Legislation regarding tax treatment of net operating losses.
Legislation regarding the Orphan Drug Act and rare disease diagnosis, treatment, and care. Newborn Screening Saves Lives Act Reauthorization, H.R. 482, S 350. FY 2022 and FY 2023 CDC Appropriations for state newborn screening technical assistance and related Senate appropriations. H.R. 1692, S 250, Fairness in Orphan Drug Exclusivity Act.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
HR 366, Protecting Access to Post-COVID-19 Telehealth Act; other legislative proposals to ensure access to telehealth services
H.R. 1730, S. 670, Speeding Therapy Access Today Act of 2021; legislation regarding diagnosis and treatment of rare kidney diseases and related nephrology issues. H.R. 3893, Coordination, Accountability, Research, and Equity for All Kidneys Act of 2021. Congressional consideration of the Prescription Drug User Fee Act. H.R. 6963, Accelerated Approval Integrity Act, and H.R. 6996, Accelerated Access for Patient Act, and Senate proposals regarding expedited FDA pathways.
Legislation regarding the Orphan Drug Act and rare disease diagnosis, treatment, and care. Newborn Screening Saves Lives Act Reauthorization, H.R. 482, S 350. FY 2022 and FY 2023 CDC Appropriations for state newborn screening technical assistance and related Senate appropriations. H.R. 1692, S 250, Fairness in Orphan Drug Exclusivity Act.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Legislation regarding the Orphan Drug Act and rare disease diagnosis, treatment, and care. Newborn Screening Saves Lives Act Reauthorization, H.R. 482, S 350. FY 2022 CDC Appropriations for state newborn screening technical assistance and related Senate appropriations. H.R. 1692, S 250, Fairness in Orphan Drug Exclusivity Act.
Provisions of H.R. 5736 Build Back Better Act and related Senate legislation regarding the Orphan Drug Tax Credit; related rare disease research incentives. Legislation regarding tax treatment of net operating losses.
HR 366, Protecting Access to Post-COVID-19 Telehealth Act; other legislative proposals to ensure access to telehealth services
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
HR 366, Protecting Access to Post-COVID-19 Telehealth Act; other legislative proposals to ensure access to telehealth services
Legislation regarding the Orphan Drug Act and rare disease diagnosis, treatment, and care. Newborn Screening Saves Lives Act Reauthorization, H.R. 482, S 350. FY 2022 CDC Appropriations for state newborn screening technical assistance and related Senate appropriations. H.R. 1692, S 250, Fairness in Orphan Drug Exclusivity Act
H.R. 1730, S. 670, Speeding Therapy Access Today Act of 2021; legislation regarding diagnosis and treatment of rare kidney diseases
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Legislative proposals regarding drug pricing, value, and reimbursement. H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act. H.R. 19, Lower Costs More Cures Act
Legislation regarding the Orphan Drug Act and rare disease diagnosis, treatment, and care. Newborn Screening Saves Lives Act Reauthorization, H.R. 482, S 350. FY 2022 CDC Appropriations for state newborn screening technical assistance. H.R. 1692, S 250, Fairness in Orphan Drug Exclusivity Act
Orphan Drug Tax Credit legislation and related rare disease research incentives. Legislation regarding tax treatment of net operating losses.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
HR 366, Protecting Access to Post-COVID-19 Telehealth Act; other legislative proposals to ensure access to telehealth services
Legislation regarding intellectual property and trademark issues
Orphan Drug Tax Credit legislation and related rare disease research incentives
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
H.R. 990 and S. 344, the Hatch-Waxman Integrity Act; S. 1416, Affordable Prescriptions for Patients Act of 2019: H.R. 3991, Affordable Prescriptions for Patients Through Improvements to Patent Litigation Act of 2019; H.R. 4398, Affordable Prescriptions for Patients Through Promoting Competition Act of 2019; Senate amendment to H.R. 2486
H.R. 1046, Medicare Price Negotiation and Competitive Licensing Act; FY 2021 Medicare and Medicaid proposals, including proposed International Pricing Index; H.R. 7078, Evaluating Disparities and Outcomes of Telehealth During the COVID-19 Emergency Act of 2020; H.R.7663, Protecting Access to Post-COVID-19 Telehealth Act of 2020; other telehealth issues; telehealth provisions in HR 133, Consolidated Appropriations Act of 2021
Rare disease patient care, screening, and coverage issues in authorization and appropriations legislation; Orphan Drug Act; H.R. 2507, S. 2158 Newborn Screening Saves Lives Act Reauthorization; FY 2021 CDC Appropriations; HR 4144, Ending the Diagnostic Odyssey Act; H.R. 5062, Advancing Access to Precision Medicine Act; H.R. 4712, S. 3271 Fairness in Orphan Drug Exclusivity Act; H.R. 534, Aidan's Law; HR 6238, Cameron's Law; rare kidney disease issues; HR 133, Consolidated Appropriations Act of 2021
Issues related to the Orphan Drug Tax Credit and Orphan Drug Act incentives; Credit for Caring Act, H.R. 2730/S. 1443; H.R. 6238, Cameron's Law; H.R. 748, CARES Act tax issues; H.R. 6900, HEROES Act tax issues; HR 133, Consolidated Appropriations Act of 2021
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
H.R. 1781, Payment Commission Data Act; H.R. 1503, Orange Book Transparency Act of 2019; H.R. 1520, Purple Book Continuity Act of 2019; H.R. 965 and S. 340, the CREATES Act; H.R. 2113, STAR Act; S. 474, SPIKE Act/Wyden; S. 1391, FAIR Drug Pricing Act; S. 1895, Lower Health Care Costs Act of 2019; H.R. 2296, FAIR/More Efficient Tools to Realize Information for Consumers Act; H.R. 987, Strengthening Health Care and Lowering Prescription Drug Costs Act; H.R. 3, Lower Drug Costs Now Act; H.R. 19, Lower Costs More Cures Act and related legislation; S. 2543, Prescription Drug Pricing Reduction Act
Rare disease patient care, screening, and coverage issues in authorization and appropriations legislation; Orphan Drug Act; H.R. 2507, S. 2158 Newborn Screening Saves Lives Act Reauthorization; FY 2021 CDC Appropriations; HR 4144, Ending the Diagnostic Odyssey Act; H.R. 5062, Advancing Access to Precision Medicine Act; H.R. 4712, S. 3271 Fairness in Orphan Drug Exclusivity Act; H.R. 534, Aidan's Law; HR 6238, Cameron's Law; rare kidney disease issues
Medical research, NIH funding, related appropriations issues; House and Senate Labor HHS Appropriations Act; FY 2021 CDC Appropriations related to newborn screening; H.R. 478, CARES Act; H.R. 6800, HEROES Act; kidney treatment and care issues
Issues related to the Orphan Drug Tax Credit and Orphan Drug Act incentives; Credit for Caring Act, H.R. 2730/S. 1443; H.R. 6238, Cameron's Law; H.R. 748, CARES Act tax issues; H.R. 6900, HEROES Act tax issues
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Issues related to the Orphan Drug Tax Credit and Orphan Drug Act incentives; Credit for Caring Act, H.R. 2730/S. 1443; H.R. 6238, Cameron's Law; H.R. 748, CARES Act tax issues
H.R. 1046, Medicare Price Negotiation and Competitive Licensing Act; FY 2021 Medicare and Medicaid proposals, including proposed International Pricing Index; H.R. 7078, Evaluating Disparities and Outcomes of Telehealth During the COVID-19 Emergency Act of 2020; telehealth access issues
Medical research, NIH funding, related appropriations issues; House and Senate Labor HHS Appropriations Act; FY 2021 CDC Appropriations related to newborn screening; H.R. 478, CARES Act; H.R. 6800, HEROES Act; kidney treatment and care issues
Rare disease patient care, screening, and coverage issues in authorization and appropriations legislation; Orphan Drug Act; H.R. 2507, S. 2158 Newborn Screening Saves Lives Act Reauthorization; FY 2021 CDC Appropriations; HR 4144, Ending the Diagnostic Odyssey Act; H.R. 5062, Advancing Access to Precision Medicine Act; H.R. 4712, S. 3271 Fairness in Orphan Drug Exclusivity Act; H.R. 534, Aidan's Law; issues related kidney care
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
H.R. 990 and S. 344, the Hatch-Waxman Integrity Act; S. 1416, Affordable Prescriptions for Patients Act of 2019: H.R. 3991, Affordable Prescriptions for Patients Through Improvements to Patent Litigation Act of 2019; H.R. 4398, Affordable Prescriptions for Patients Through Promoting Competition Act of 2019; Senate amendment to H.R. 2486
H.R. 1781, Payment Commission Data Act; H.R. 1503, Orange Book Transparency Act of 2019; H.R. 1520, Purple Book Continuity Act of 2019; H.R. 965 and S. 340, the CREATES Act; H.R. 2113, STAR Act; S. 474, SPIKE Act/Wyden; S. 1391, FAIR Drug Pricing Act; S. 1895, Lower Health Care Costs Act of 2019; H.R. 2296, FAIR/More Efficient Tools to Realize Information for Consumers Act; H.R. 987, Strengthening Health Care and Lowering Prescription Drug Costs Act; H.R. 3, Lower Drug Costs Now Act; H.R. 19, Lower Costs More Cures Act and related legislation
Issues related to the Orphan Drug Tax Credit and Orphan Drug Act incentives; Credit for Caring Act, H.R. 2730/S. 1443; H.R. 6238, Cameron's Law
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
H.R. 1781, Payment Commission Data Act; H.R. 1503, Orange Book Transparency Act of 2019; H.R. 1520, Purple Book Continuity Act of 2019; H.R. 965 and S. 340, the CREATES Act; H.R. 2113, STAR Act; S. 474, SPIKE Act/Wyden; S. 1391, FAIR Drug Pricing Act; S. 1895, Lower Health Care Costs Act of 2019; H.R. 2296, FAIR/More Efficient Tools to Realize Information for Consumers Act; H.R. 987, Strengthening Health Care and Lowering Prescription Drug Costs Act; H.R. 3, Lower Drug Costs Now Act; H.R. 19, Lower Costs More Cures Act and related legislation
Medical research, NIH funding, related appropriations issues; Senate Labor HHS Appropriations Act; H.R.1158, Consolidated Appropriations Act of 2020
Issues related to the Orphan Drug Tax Credit and Orphan Drug Act incentives; Credit for Caring Act, H.R. 2730/S. 1443
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
H.R. 1046, Medicare Price Negotiation and Competitive Licensing Act; FY 2020 Medicare and Medicaid proposals, including proposed International Pricing Index
H.R. 1781, Payment Commission Data Act; H.R. 1503, Orange Book Transparency Act of 2019; H.R. 1520, Purple Book Continuity Act of 2019; H.R. 965 and S. 340, the CREATES Act; H.R. 2113, STAR Act; S. 474, SPIKE Act/Wyden; S. 1391, FAIR Drug Pricing Act; S. 1895, Lower Health Care Costs Act of 2019; H.R. 2296, FAIR/More Efficient Tools to Realize Information for Consumers Act; H.R. 987, Strengthening Health Care and Lowering Prescription Drug Costs Act
Issues related to the Orphan Drug Tax Credit and Orphan Drug Act incentives; Credit for Caring Act, H.R. 2730/S. 1443
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
H.R. 1781, Payment Commission Data Act; H.R. 1503, Orange Book Transparency Act of 2019; H.R. 1520, Purple Book Continuity Act of 2019; H.R. 965 and S. 340, the CREATES Act; H.R. 2113, STAR Act; S. 474, SPIKE Act/Wyden; S. 1391, FAIR Drug Pricing Act; S. 1895, Lower Health Care Costs Act of 2019; H.R. 2296, FAIR/More Efficient Tools to Realize Information for Consumers Act
Issues related to the Orphan Drug Tax Credit; Credit for Caring Act, H.R. 2730/S. 1443
H.R. 990 and S. 344, the Hatch-Waxman Integrity Act; S. 1416, Affordable Prescriptions for Patients Act of 2019
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Medical research, NIH funding, related appropriations issues
H.R. 1781, Payment Commission Data Act; H.R. 1503, Orange Book Transparency Act of 2019; H.R. 1520, Purple Book Continuity Act of 2019; H.R. 965 and S. 340, the CREATES Act
Rare disease patient care, screening, and coverage issues in authorization and appropriations legislation; Orphan Drug Act; HRes 242, Affirming importance of Orphan Drug Act
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Orphan Drug Act, Drug Quality and Security Act drug safety issues, drug pricing, opioid legislation provisions related to opioid sparing, FAST Generics and CREATES Acts, FDA issues
FY 2019 budget proposals with respect to Medicare and Medicaid reform
Rare disease patient care, screening, and coverage issues in authorization and appropriations legislation, S 1151 Credit for Caring Act, SRes 690 and HRes1154, Orphan Drug Act anniversary
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Medical research, NIH funding, related appropriations issues
Intellectual property issues and commercial litigation, including S. 1390 and H.R. 5390, STRONGER Patents Act
Tax legislation relating to the Orphan Drug Tax Credit, development, and rare disease patient issues; implementation of HR 1, the Tax Cuts and Jobs Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Intellectual property issues and commercial litigation, including S. 1390 and H.R. 5390, STRONGER Patents Act
Tax legislation relating to the Orphan Drug Tax Credit, development, and rare disease patient issues; implementation of HR 1, the Tax Cuts and Jobs Act.
Medical research, NIH funding, related appropriations issues
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Rare disease patient care, screening, and coverage issues in authorization and appropriations legislation, including Omnibus Appropriations Act.
Orphan Drug Act, Drug Quality and Security Act drug safety issues, drug pricing, Prescription Drug User Fee Act reauthorization and implementation, FAST Generics and CREATES Acts, FDA issues
FY 2019 budget proposals with respect to Medicare and Medicaid reform provisions, including rebate and coverage provisions in the HR 1892, Bipartisan Budget Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
HR 1, the Tax Cuts and Jobs Act, provisions relating to the Orphan Drug Tax Credit, development, and rare disease patient issues
Intellectual property issues and commercial litigation
Orphan Drug Act, Drug Quality and Security Act drug safety issues, drug pricing, Prescription Drug User Fee Act reauthorization, FAST Generics and CREATES Acts, FDA issues
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Intellectual property issues and commercial litigation
American Health Care Act and Better Care Reconciliation Act Medicaid provisions.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
American Health Care Act Medicaid provisions.
Rare disease patient care, screening, and coverage issues in American Health Care Act and Better Care Reconciliation Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Intellectual property issues and commercial litigation
Orphan Drug Act, Drug Quality and Security Act drug safety issues, drug pricing, Prescription Drug User Fee Act reauthorization, FAST Generics and CREATES Acts, FDA issues
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Orphan Drug Act, Drug Quality and Security Act, drug pricing, Prescription Drug User Fee Act reauthorization, FDA issues
Intellectual property issues and commercial litigation
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
HR 6, 21st Century Cures Act and related Senate legislation Orphan Drug Act and related issues Drug Quality and Security Act, proposed revisions and implementation Rare diseases patient care and screening issues Intellectual property Drug pricing
HR 6, 21st Century Cures Act and related Senate legislation Orphan Drug Act and related issues Drug Quality and Security Act, proposed revisions and implementation Rare diseases patient care and screening issues Intellectual property Drug pricing